Prometa

Small molecule

UUniversity of California, Los Angeles

Prometa is one of 36 small molecule programs targeting Methamphetamine Dependence. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Methamphetamine DependenceActive, not recruiting

Methamphetamine DependencePhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Methamphetamine Dependence

#DrugCompanyPhaseTrials

Provigil

NNuvo Research GmbH

Approved

9 2

Minipress

Abilify

3 4

Acetadote

AArbor Pharmaceuticals, Inc.

Suboxone

Campral

Prometrium

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Risperdal

Revia

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Methamphetamine Dependence1 trial

Prometa Pharmacotherapy for Methamphetamine Dependence

Completed·UUniversity of California, Los Angeles·Phase 2/3·NCT00260481·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Prometa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prometa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prometa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversity of California, Los Angeles

Prometa

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Methamphetamine Dependence1 trial

References

Drug Info

Quick Facts

Related News